Meet our
Management

Vice President of New Product Development

With 20 years of experience in new product and process development in the medical device, drug delivery and specialty chemicals fields, Paul manages and leads all aspects of VT’s product development, CMC, and technical operations.

Prior to joining Vascular Therapies in 2008, Paul was a Program Manager at Arsenal Capital Partners (a leading New York-based private equity firm). Before working with Arsenal, he was a Staff Engineer at Cordis Corporation (a Johnson & Johnson company) developing drug-device combination products, including drug-eluting stents and bioabsorbable drug delivery systems. He brings a wealth of technical skills and experience to Vascular Therapies, as well as a deep understanding of medical device and pharmaceutical quality systems and regulatory requirements.

Paul graduated from Bucknell University with a B.A. in Liberal Arts and a B.S. in Chemical Engineering and earned his Ph.D. in Chemical Engineering from Princeton University.

CAUTION: THE SIROLIMUS-ELUTING COLLAGEN IMPLANT (SIROGENTM) IS AN INVESTIGATIONAL PRODUCT THAT IS NOT AVAILABLE FOR SALE IN ANY COUNTRY. READ OUR Expanded Access Policy.